Scientific Publications-2007-Malaria

2007

Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Senegal by Brasseur P, Agnamey P, Gaye O, Vaillant M, Taylor WR, Olliaro PL. Malar J. 2007 Nov 15; 6:150.
Artesunate plus amodiaquine (AS+AQ) was used to treat slide-proven Plasmodium falciparum-infected patients of all ages in the Oussouye district, Casamance, Senegal, over a period of six years (2000 to 2005). AS+AQ in combination was highly efficacious and well-tolerated in this area and justifies the decision to use it as first line treatment. Long-term monitoring of safety and efficacy should continue.
Click here to download the full article [PDF]

An analytical method with a single extraction procedure and two separate high performance liquid chromatographic systems for the determination of artesunate, dihydroartemisinin and mefloquine in human plasma for application in clinical pharmacological studies of the drug combination by Lai CS, Nair NK, Mansor SM, Olliaro PL, Navaratnam V. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Oct 1; 857(2): 308-14.
The combination of two sensitive, selective and reproducible reversed phase liquid chromatographic (RP-HPLC) methods was developed for the determination of artesunate (AS), its active metabolite dihydroartemisinin (DHA) and mefloquine (MQ) in human plasma. The method was found to be suitable for use in clinical pharmacological studies.
Click here to access the full article

Artesunate – amodiaquine for the treatment of uncomplicated malaria by Sirima SB, Gansane A. Expert Opin Investig Drugs. 2007 Jul;16(7): 1079-85.
Without an effective vaccine for the prevention of malaria, a fundamental component of the strategy for the control of this disease is based on prompt and effective treatment. An important step is the recent registration in Morocco (the country where the drug is manufactured) of a fixed combination of artesunate plus amodiaquine by the Drugs for Neglected Diseases initiative with sanofi-aventis as the industrial partner.
Click here to access the full article

Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo by Vivas L, Rattray L, Stewart LB, Robinson BL, Fugmann B, Haynes RK, Peters W, Croft SL. J Antimicrob Chemother. 2007 Apr; 59(4): 658-65. Epub 2007 Mar 2.
The in vitro and in vivo efficacy and drug–drug interactions of the novel semi-synthetic endoperoxide artemisone with standard antimalarials were investigated in order to provide the basis for the selection of the best partner drug. Artemisone represents an important addition to the repertoire of artemisinin combination therapies currently in use, as it has enhanced antimalarial activity, improved bioavailability and stability over current endoperoxides.
Click here to download the full article [PDF]

L’ASAQ, une avancée dans la lutte contre le paludisme by Kiechel JR, Pecoul B. Med Trop 2007; 67: 109-110.
This editorial (in French) presents ASAQ, a fixed-dose combination of artesunate and amodiaquine launched in March 2007 by Drugs for Neglected Diseases initiative (DNDi) and sanofi-aventis. The combination is aimed for treating uncomplicated falciparum malaria in malaria-endemic countries in Africa.
Click here to download the full article [PDF]